Skip to content

Study · Observational study · n = 5,224 · 2025

9 results

Semaglutide 2.4 mg Clinical Outcomes in Patients with Obesity or Overweight: A Real-World Retrospective Comparative Cohort Study.

Ruseva A, Michalak W, Fabricatore A, Hartaigh BÓ, Zhao Z, Umashanker D

Advances in therapy6 Aug 2025Cited by 4 (Europe PMC)

PMID40768189 (opens in a new tab)PMCIDPMC12474578 (opens in a new tab)DOI10.1007/s12325-025-03320-6 (opens in a new tab)PepBankPUB-40768189
Read at sourcePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with obesity or overweight, semaglutide 2.4 mg gave a 15.0% greater reduction in weight than no obesity medication at 12 months.

    In plain wordsIn adults with obesity or overweight, those on semaglutide 2.4 mg lost 15.0% more weight than similar people on no obesity medication at 12 months.

    Peptide
    Semaglutide
    Outcome
    DecreasePercentage change in weight
    Study

    n = 5,224

    Comparator
    No obesity medication
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg · 12 monthsAs given in this study (human).

    Measurements

    Estimated treatment difference in weight
    15%
    12 months

    Source sentences

    Summary
    significantly greater percentage (- 15.0%)
    2 context sentences
    Summary · context
    This real-world, retrospective, observational cohort study included adults with obesity or overweight with ≥ 1 obesity-related complication treated with semaglutide 2.4 mg identified in a large US claims and medical record database (December 15, 2020, through May 30, 2024).
    Summary · context
    Patients were matched 1:4 to non-treated patients using a propensity score (PS) model.
  2. 02HumanObservational studyEfficacy outcome

    In adults with obesity or overweight, semaglutide 2.4 mg gave a 15.7 kg greater absolute weight reduction than no obesity medication at 12 months.

    In plain wordsIn adults with obesity or overweight, those on semaglutide 2.4 mg lost 15.7 kg more than similar people on no obesity medication at 12 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseAbsolute weight change
    Study

    n = 5,224

    Comparator
    No obesity medication
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg · 12 monthsAs given in this study (human).

    Measurements

    Estimated treatment difference in weight
    15.7 kg
    12 months

    Source sentences

    Summary
    absolute reduction in weight (- 15.7 kg)
    2 context sentences
    Summary · context
    This real-world, retrospective, observational cohort study included adults with obesity or overweight with ≥ 1 obesity-related complication treated with semaglutide 2.4 mg identified in a large US claims and medical record database (December 15, 2020, through May 30, 2024).
    Summary · context
    Patients were matched 1:4 to non-treated patients using a propensity score (PS) model.
  3. 03HumanObservational studyEfficacy outcome

    In adults with obesity or overweight, semaglutide 2.4 mg gave a 4.2 kg/m2 greater BMI reduction than no obesity medication at 12 months.

    In plain wordsIn adults with obesity or overweight, BMI fell 4.2 points more on semaglutide 2.4 mg than with no obesity medication at 12 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseBMI change
    Study

    n: not reported in source

    Comparator
    No obesity medication
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg · 12 monthsAs given in this study (human).

    Measurements

    Estimated treatment difference in BMI
    4.2 kg/m<sup>2</sup>
    12 months

    Source sentences

    Summary
    greater reduction in BMI (- 4.2 kg/m2)
    2 context sentences
    Summary · context
    This real-world, retrospective, observational cohort study included adults with obesity or overweight with ≥ 1 obesity-related complication treated with semaglutide 2.4 mg identified in a large US claims and medical record database (December 15, 2020, through May 30, 2024).
    Summary · context
    Patients were matched 1:4 to non-treated patients using a propensity score (PS) model.
  4. 04HumanObservational studyEfficacy outcome

    In adults with obesity or overweight, semaglutide 2.4 mg gave a 6.7 mmHg greater reduction in systolic blood pressure than no obesity medication at 12 months.

    In plain wordsIn adults with obesity or overweight, systolic blood pressure fell 6.7 mmHg more on semaglutide 2.4 mg than with no obesity medication.

    Peptide
    Semaglutide
    Outcome
    DecreaseSystolic blood pressure change
    Study

    n: not reported in source

    Comparator
    No obesity medication
    Analysis
    Secondary
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    2.4 mg · 12 monthsAs given in this study (human).

    Measurements

    Estimated treatment difference in SBP
    6.7 mmHg
    12 months

    Source sentences

    Summary
    SBP (- 6.7 mmHg)
    2 context sentences
    Summary · context
    This real-world, retrospective, observational cohort study included adults with obesity or overweight with ≥ 1 obesity-related complication treated with semaglutide 2.4 mg identified in a large US claims and medical record database (December 15, 2020, through May 30, 2024).
    Summary · context
    Patients were matched 1:4 to non-treated patients using a propensity score (PS) model.
  5. 05HumanObservational studyEfficacy outcome

    In adults with obesity or overweight, semaglutide 2.4 mg gave a 2.7 mmHg greater reduction in diastolic blood pressure than no obesity medication at 12 months.

    In plain wordsIn adults with obesity or overweight, diastolic blood pressure fell 2.7 mmHg more on semaglutide 2.4 mg than with no obesity medication.

    Peptide
    Semaglutide
    Outcome
    DecreaseDiastolic blood pressure change
    Study

    n: not reported in source

    Comparator
    No obesity medication
    Analysis
    Secondary
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    2.4 mg · 12 monthsAs given in this study (human).

    Measurements

    Estimated treatment difference in DBP
    2.7 mmHg
    12 months

    Source sentences

    Summary
    DBP (- 2.7 mmHg)
    2 context sentences
    Summary · context
    This real-world, retrospective, observational cohort study included adults with obesity or overweight with ≥ 1 obesity-related complication treated with semaglutide 2.4 mg identified in a large US claims and medical record database (December 15, 2020, through May 30, 2024).
    Summary · context
    Patients were matched 1:4 to non-treated patients using a propensity score (PS) model.
  6. 06HumanObservational studyEfficacy outcome

    In adults with obesity or overweight, semaglutide 2.4 mg gave a 0.5% greater reduction in HbA1c than no obesity medication at 12 months.

    In plain wordsIn adults with obesity or overweight, HbA1c fell 0.5% more on semaglutide 2.4 mg than with no obesity medication.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change
    Study

    n: not reported in source

    Comparator
    No obesity medication
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2.4 mg · 12 monthsAs given in this study (human).

    Measurements

    Estimated treatment difference in HbA1c
    0.5%
    12 months

    Source sentences

    Summary
    HbA1c (- 0.5%)
    2 context sentences
    Summary · context
    This real-world, retrospective, observational cohort study included adults with obesity or overweight with ≥ 1 obesity-related complication treated with semaglutide 2.4 mg identified in a large US claims and medical record database (December 15, 2020, through May 30, 2024).
    Summary · context
    Patients were matched 1:4 to non-treated patients using a propensity score (PS) model.
  7. 07HumanObservational studyEfficacy outcome

    In adults with obesity or overweight, semaglutide 2.4 mg gave a 1.2 mg/dl greater increase in HDL cholesterol than no obesity medication at 12 months.

    In plain wordsIn adults with obesity or overweight, HDL cholesterol rose 1.2 mg/dl more on semaglutide 2.4 mg than with no obesity medication.

    Peptide
    Semaglutide
    Outcome
    IncreaseHDL cholesterol change
    Study

    n: not reported in source

    Comparator
    No obesity medication
    Analysis
    Secondary
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    2.4 mg · 12 monthsAs given in this study (human).

    Measurements

    Estimated treatment difference in HDL-C
    1.2 mg/dl
    12 months

    Source sentences

    Summary
    HDL-C (1.2 mg/dl)
    2 context sentences
    Summary · context
    This real-world, retrospective, observational cohort study included adults with obesity or overweight with ≥ 1 obesity-related complication treated with semaglutide 2.4 mg identified in a large US claims and medical record database (December 15, 2020, through May 30, 2024).
    Summary · context
    Patients were matched 1:4 to non-treated patients using a propensity score (PS) model.
  8. 08HumanObservational studyEfficacy outcome

    In adults with obesity or overweight, semaglutide 2.4 mg gave a 10.4 mg/dl greater reduction in LDL cholesterol than no obesity medication at 12 months.

    In plain wordsIn adults with obesity or overweight, LDL cholesterol fell 10.4 mg/dl more on semaglutide 2.4 mg than with no obesity medication.

    Peptide
    Semaglutide
    Outcome
    DecreaseLDL cholesterol change
    Study

    n: not reported in source

    Comparator
    No obesity medication
    Analysis
    Secondary
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    2.4 mg · 12 monthsAs given in this study (human).

    Measurements

    Estimated treatment difference in LDL-C
    10.4 mg/dl
    12 months

    Source sentences

    Summary
    LDL-C (- 10.4 mg/dl)
    2 context sentences
    Summary · context
    This real-world, retrospective, observational cohort study included adults with obesity or overweight with ≥ 1 obesity-related complication treated with semaglutide 2.4 mg identified in a large US claims and medical record database (December 15, 2020, through May 30, 2024).
    Summary · context
    Patients were matched 1:4 to non-treated patients using a propensity score (PS) model.
  9. 09HumanObservational studyEfficacy outcome

    In adults with obesity or overweight, semaglutide 2.4 mg gave a 34.3 mg/dl greater reduction in triglycerides than no obesity medication at 12 months.

    In plain wordsIn adults with obesity or overweight, triglycerides fell 34.3 mg/dl more on semaglutide 2.4 mg than with no obesity medication.

    Peptide
    Semaglutide
    Outcome
    DecreaseTriglyceride change
    Study

    n: not reported in source

    Comparator
    No obesity medication
    Analysis
    Secondary
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    2.4 mg · 12 monthsAs given in this study (human).

    Measurements

    Estimated treatment difference in triglycerides
    34.3 mg/dl
    12 months

    Source sentences

    Summary
    and triglycerides (- 34.3 mg/dl)
    2 context sentences
    Summary · context
    This real-world, retrospective, observational cohort study included adults with obesity or overweight with ≥ 1 obesity-related complication treated with semaglutide 2.4 mg identified in a large US claims and medical record database (December 15, 2020, through May 30, 2024).
    Summary · context
    Patients were matched 1:4 to non-treated patients using a propensity score (PS) model.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.